scholarly journals In Search of a Histopathological Pattern of Immune-Mediated Gastritis from Nivolumab Therapy: A Case Report with Literature Review

2021 ◽  
pp. 1-3
Author(s):  
Flor M Fernández-Gordón Sánchez ◽  
Flor M Fernández-Gordón Sánchez ◽  
Elena Gomez Dominguez ◽  
Cristina Garfia Castillo ◽  
Jorge Arroyo Andres ◽  
...  
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Literature Review ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Gastrointestinal Symptoms ◽  
Specific Pattern ◽  
Immune Mediated ◽  
Upper Gastrointestinal Symptoms ◽  
Upper Gastrointestinal

Immunotherapy with checkpoint inhibitors is associated with termed inflammatory and immune-related side effects (irAE). Upper gastrointestinal symptoms are infrequent and appear mainly in patients on combination therapy with two checkpoint inhibitor drugs. We present the case of a patient with IIIB stage cutaneous melanoma treated with Nivolumab in monotherapy who developed an immune-mediated gastritis. Histopathologically, due to the paucity of published cases, no specific pattern of Nivolumab-immune-mediated gastritis has been described. We have reviewed the literature and compared the histopathology of the cases available in the literature.

scholarly journals Az onkológiában alkalmazott immuncheckpointgátló terápiák autoimmun mellékhatásai: patogenezis, klinikum és terápia

2019 ◽  
Vol 160 (23) ◽  
pp. 887-895
Author(s):  
Éva Szekanecz ◽  
Zoltán Szekanecz
Keyword(s):  
Side Effects ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Current View ◽  
Immune Mediated ◽  
Underlying Malignancy ◽  
Organ Specific ◽  
Checkpoint Inhibitor Therapy

Abstract: Oncotherapy has been revolutionised by the introduction of immune-checkpoint inhibitors including CTLA4, PD1 and PDL1 inhibitors. Patients with malignant diseases may largely benefit from these therapies, which may result in long-term remission even in the most therapy-resistant tumour types. Differences in the mode of action of the various agents may result in varying side-effect profiles. In addition to organ-specific side-effects, overt autoimmune syndromes may also develop. Our current view of oncotherapy has changed as these mostly immune-mediated side-effects highly differ from those observed previously during the administration of traditional anti-tumour compounds. These side-effects should be carefully characterized and differentiated from infections or the progression of the underlying malignancy. Fortunately, several recent recommendations have become available on the management of immune-mediated adverse events due to checkpoint-inhibitor therapy. Orv Hetil. 2019; 160(23): 887–895.

Sign in / Sign up

Export Citation Format

Share Document